,Canonical_Smiles,drug_name,drug_type,Label
0,c1ccc2ncccc2c1,quinoline,2E1-Substrate,negative
1,Oc1ncnc2[nH]ncc12,Allopurinol,2E1-Inhibitor,positive
2,C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)Nc1cc(C(F)(F)F)ccc1C(F)(F)F,Dutasteride,-,negative
3,CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc(Cl)c1Cl,Clevidipine,2C9-Inhibitor,negative
4,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314,Oxycodone,19A-Inhibitor,negative
5,CN(CCCN1c2ccccc2CCc2ccccc21)CC(=O)c1ccc(Cl)cc1,Lofepramine,2D6-Substrate,negative
6,O=C1c2ccccc2C(=O)c2ccccc21,Anthraquinone,-,negative
7,Clc1ccc(CO[C@@H](C[C@H]2C=NC=N2)c2ccc(Cl)cc2Cl)cc1,Econazole,2E1-Inhibitor,positive
8,O=C1CN(N=Cc2ccc([N+](=O)[O-])o2)C(=O)N1,Nitrofurantoin,ATP_binding_cassette_sub_family_G_member_2-Substrate,negative
9,Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1,Nevirapine,2D6-Substrate,negative
10,NCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1,Norfluoxetine,2D6-Substrate,negative
11,Cc1cnc2ccc3c(nc(N)n3C)c2n1,2_amino_3_8_dimethylimidazo_4_5_f_quinoxaline,1A2-Substrate,negative
12,CCN(CC)C(=O)C(C#N)=Cc1cc(O)c(O)c([N+](=O)[O-])c1,Entacapone,2E1-Inhibitor,positive
13,C[C@@H]1C[C@H]2[C@H]3CCC4=CC(=O)C=C[C@@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,Clobetasol,1A2-Inhibitor,negative
14,Cc1cc(=O)n(-c2ccccc2)n1C,Phenazone,CP2CI-Substrate,negative
15,CCCCC(C(=O)OC1CCN(C)CC1)(c1ccccc1)c1ccccc1,Propiverine,3A4-Inhibitor,negative
16,CCN(CC)C(=S)SSC(=S)N(CC)CC,Disulfiram,2E1-Inhibitor,positive
17,c1ccc(-c2ccc([C@H](c3ccccc3)n3ccnc3)cc2)cc1,Bifonazole,2E1-Inhibitor,positive
18,CN(C)CCOC(c1ccccc1)c1ccccc1,Diphenhydramin,2D6-Substrate,negative
19,CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(=O)O,Bezafibrate,Solute_carrier_organic_anion_transporter_family_member_1B1-Inhibitor,negative
20,NCc1ccc(C(=O)O)cc1,Aminomethylbenzoic Acid,Solute_carrier_family_15_member_1-Inhibitor,negative
21,OC[C@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@@H]3[C@@H](O)[C@H](O[C@@H]4[C@@H](O)[C@H](O[C@@H]5[C@@H](O)[C@H](O)O[C@H](CO[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)[C@H]5O)O[C@H](CO)[C@H]4O)O[C@H](CO)[C@H]3O)O[C@H](CO[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,Lentinan,GST-Inhibitor,negative
22,CC(C)C[C@@H](N(C)C)C1(c2ccc(Cl)cc2)CCC1,Sibutramine,-,negative
23,COc1ccc2c(c1OC)C(=O)O[C@H]2[C@H]1c2c(cc3c(c2OC)OCO3)CCN1C,Noscapine,2C19-Inhibitor,negative
24,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1,Amprenavir,2D6-Substrate,negative
25,CNC(=O)Oc1ccc2c(c1)[C@]1(C)CCN(C)[C@@H]1N2C,Physostigmine,Methyltransferase-Inhibitor,negative
26,C[C@H](NCCc1ccc(O)cc1)[C@H](O)c1ccc(O)cc1,Ritodrine,SUL-Substrate,negative
27,C[C@]12C[C@@H]3C[C@](C)(C1)C[C@@](N)(C3)C2,Memantine,2D6-Inhibitor,negative
28,C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@]32OO4,Artemisinin,GST-Inhibitor,negative
29,NCCS,Mercaptamine,GST-Inhibitor,negative
30,O=C(O)COc1ccc(C(=O)c2ccsc2)c(Cl)c1Cl,tienilic_acid_deriv_3_isomer,2C9-Substrate,negative
31,COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1,Indometacin,GST-Inhibitor,negative
32,O=C(Nc1ccc2c(=O)cc(-c3nnn[nH]3)oc2c1)c1ccc(OCCCCc2ccccc2)cc1,Pranlukast,Solute_carrier_family_22_member_11-Inhibitor,negative
33,O=C1OC(c2ccc(O)c(S(=O)(=O)O)c2)(c2ccc(O)c(S(=O)(=O)O)c2)c2c(Br)c(Br)c(Br)c(Br)c21,Sulfobromophthalein,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
34,N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,Melphalan,GST-Substrate,negative
35,CC(=O)Nc1ccc2c(c1)Cc1ccccc1-2,2_acetylamino_fluorene,1A2-Substrate,negative
36,CN[C@@]1(c2ccccc2Cl)CCCCC1=O,Ketamine,2D6-Substrate,negative
37,CNCCCC1c2ccccc2C=Cc2ccccc21,Protriptyline,2D6-Substrate,negative
38,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1c1ccccc1C=CC(=O)OC(C)(C)C,Lacidipine,-,negative
39,CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1,Benzbromarone,-,negative
40,COc1ccc([C@H](CC(=O)O)N2CCN(CCCc3ccc4c(n3)NCCC4)C2=O)cn1,compound_A,2D6-Substrate,negative
41,COc1ccc2c3c1O[C@H]1C(=O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314,Hydrocodone,2D6-Substrate,negative
42,CO[C@@H]1C[C@H](O[C@@H]2[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](O)[C@@H](C)C(=O)[C@@]3(CO3)C[C@H](C)[C@H](O[C@H]3O[C@@H](C)C[C@@H](N(C)C)[C@H]3O)[C@H]2C)O[C@@H](C)[C@H]1O,Oleandomycin,UGT-Substrate,negative
43,O=c1[nH]c2cc(Cl)ccc2o1,chlorzoxazone,2E1-Substrate,negative
44,CC(N)Cc1ccc2c(c1)OCO2,MDA_tenamfetamine,2D6-Substrate,negative
45,Nc1ccc(C(=O)O)cc1,Aminobenzoic Acid,SUL-Substrate,negative
46,CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1,Melperone,2D6-Inhibitor,negative
47,CCCSc1ccc2[nH]c(NC(=O)OC)nc2c1,Albendazole,2D6-Substrate,negative
48,CCCC(CCC)C(=O)O,Valproic Acid,4A11-Inducer,negative
49,CSc1nc(-c2ccnc(NC(C)c3ccccc3)c2)c(-c2ccc(F)cc2)[nH]1,ML_3403,2D6-Substrate,negative
50,CCCCNC(C)Cc1ccc(OC)cc1,4_methoxy_N_butylamphetamine,2D6-Substrate,negative
51,COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3,Dextromethorphan,2E1-Substrate,negative
52,COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC,Prazosin,Solute_carrier_family_22_member_1-Inhibitor,negative
53,c1ccc2c(c1)Sc1ccccc1N2C[C@@H]1CN2CCC1CC2,mequitazine,2D6-Substrate,negative
54,CN(CC=CC#CC(C)(C)C)Cc1cccc2ccccc12,Terbinafine,19A-Inhibitor,negative
55,COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)[C@H]1c1cccc([N+](=O)[O-])c1,Nilvadipine,2E1-Substrate,negative
56,CC(C)=CCN1CCC2(C)c3cc(O)ccc3CC1C2C,Pentazocine,2D6-Substrate,negative
57,Cc1c[nH]c2ccccc12,3_methylindole,2E1-Substrate,negative
58,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)C=C(C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)C=CC=CC=C1C,Sirolimus,P450_HFLA-Substrate,negative
59,C#CCNC1CCc2ccccc21,Rasagiline,1A2-Substrate,negative
60,COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1,Buflomedil,2D6-Substrate,negative
61,CCN(CC)CCS(=O)(=O)C1CCN2C(=O)c3coc(n3)CC(=O)CC(O)C=C(C)C=CCNC(=O)C=CC(C)C(C(C)C)OC(=O)C12,Dalfopristin,-,negative
62,CC[C@]1(C)CC(=O)NC1=O,Ethosuximide,2E1-Substrate,negative
63,CN(C)CCC=C1c2ccccc2COc2ccc(CC(=O)O)cc21,Olopatadine,-,negative
64,Cc1ccc(C(=CCN2CCCC2)c2ccccn2)cc1,Triprolidine,2D6-Inhibitor,negative
65,C/C=C/C,trans_2_butene,2E1-Substrate,negative
66,OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,Sorbitol,1A2-Inhibitor,negative
67,Clc1ccc([C@@H](Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1,Sertaconazole,Sterol_14_alpha_demethylase_Lanosterol_14_alpha_demethylase-Inhibitor,negative
68,Cc1cccc(C)c1NC(=O)CC12CCCN1CCC2,Pilsicainide,-,negative
69,CCN(CC)N=O,NN_diethyl_nitrosoamine,2E1-Substrate,negative
70,CSCC[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)O,Corticotropin,SUL-Inducer,negative
71,COc1ccc2c(C[n+]3ccccc3)cc(=O)oc2c1,MMPyrC,2D6-Substrate,negative
72,FC(F)(F)C(Cl)Br,halothane,2E1-Substrate,negative
73,C[C@]12CC[C@H]3[C@@H](CCC4=C(O)C(=O)CC[C@@]43C)[C@@H]1CCC2=O,Formestane,19A-Inhibitor,negative
74,Nc1ccc(Cc2ccc(N)c(Cl)c2)cc1Cl,MOCA,3A4-Substrate,negative
75,CC(C)OC(=O)CCCC=CC[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,Latanoprost,Solute_carrier_organic_anion_transporter_family_member_2A1-Inhibitor,negative
76,O=C(O)c1cccnc1Nc1cccc(C(F)(F)F)c1,Niflumic Acid,Monocarboxylate_transporter_1-Inhibitor,negative
77,Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1,tolterodine,2D6-Substrate,negative
78,CC(C)[C@]12CC(=O)[C@H](C)[C@H]1C2,alpha_thujone,3A4-Substrate,negative
79,CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,Methotrexate,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
80,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,Raloxifene,19A-Inhibitor,negative
81,Cc1c(C)c2c(c(C)c1O)CC[C@](C)(COc1ccc(C[C@@H]3SC(=O)NC3=O)cc1)O2,Troglitazone,19A-Inhibitor,negative
82,C[C@@H](O)C(=O)O,Milchs√§ure,Monocarboxylate_transporter_1-Substrate,negative
83,CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)cc1N,Retigabine,1A1-Substrate,negative
84,CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12,Eletriptan,2D6-Substrate,negative
85,CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1,Fosamprenavir,2C19-Inhibitor,negative
86,CN1[C@H]2CCC[C@@H]1C[C@@H](NC(=O)c1nn(C)c3ccccc13)C2,Granisetron,2D6-Substrate,negative
87,Clc1ccc(C(c2ccc(Cl)cc2)C(Cl)(Cl)Cl)cc1,Clofenotane,19A-Inhibitor,negative
88,CNNCc1ccc(C(=O)NC(C)C)cc1,Procarbazine,1B1-Substrate,negative
89,CC12CCC(=O)C=C1C1CC1C1C2CCC2(C)C1C1CC1C21CCC(=O)O1,Drospirenone,-,negative
90,Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,Azathioprine,Methyltransferase-Substrate,negative
91,N[Pt](N)(Cl)Cl,Cisplatin,Probable_low_affinity_copper_uptake_protein_2-Substrate,negative
92,Clc1ccc([C@H](Cn2ccnc2)OCc2c(Cl)cccc2Cl)c(Cl)c1,Isoconazole,19A-Inhibitor,negative
93,C#C[C@]1(O)CC[C@H]2[C@H]3CCC4=CC(=O)CC[C@H]4[C@H]3C(=C)C[C@]21CC,Etonogestrel,-,negative
94,CC1(C)[C@@H](C=C(Br)Br)[C@H]1C(=O)O[C@H](C#N)c1cccc(Oc2ccccc2)c1,Decamethrin,1A2-Substrate,negative
95,NNC(=O)c1ccncc1,Isoniazid,2E1-Inhibitor,positive
96,COc1ccc2c3c1O[C@H]1C[C@@H](O)C=C[C@@]31CCN(C)C2,Galantamine,2D6-Substrate,negative
97,O=C(NCCN1CCOCC1)c1ccc(Cl)cc1,Moclobemide,Methyltransferase-Inhibitor,negative
98,CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(=O)O,Benzylpenicillin,Canalicular_multispecific_organic_anion_transporter_1-Inducer,negative
99,CCNc1nc(Cl)nc(NC(C)C)n1,atrazine,2E1-Substrate,negative
100,O=C1C(=C2Nc3ccc(S(=O)(=O)[O-])cc3C2=O)Nc2ccc(S(=O)(=O)[O-])cc21,Indigo Carmine,Coumarin_7_hydroxylase-Inhibitor,negative
101,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@H]3[C@H](CC[C@@]21C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O,Chenodeoxycholic Acid,GST-Inhibitor,negative
102,CC(C)CCC[C@@H](C)[C@@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@@]4(C)[C@@H]3C[C@H](O)[C@]12C,5beta_cholestane_3alpha_7alpha_12alpha_triol,2C19-Substrate,negative
103,C[C@H](C(=O)O)c1ccc(N2CC=CC2)c(Cl)c1,Pirprofen,UGT-Substrate,negative
104,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,Mometasone,2C8-Inhibitor,negative
105,CCN(C)C(=O)Oc1cccc([C@H](C)N(C)C)c1,Rivastigmine,2D6-Inhibitor,negative
106,CCCCCNC(=N)NN=Cc1c[nH]c2ccc(CO)cc12,Tegaserod,2E1-Inhibitor,positive
107,O=c1oc2ccccc2c(O)c1Cc1c(O)c2ccccc2oc1=O,Dicoumarol,GST-Inhibitor,negative
108,COc1cc2c(cc1OC)[C@@H]1CC(=O)[C@@H](CC(C)C)CN1CC2,Tetrabenazine,2D6-Inhibitor,negative
109,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(=O)O,Quinapril,Solute_carrier_family_15_member_2-Inhibitor,negative
110,C=CCc1ccccc1OC[C@@H](O)CNC(C)C,Alprenolol,2D6-Substrate,negative
111,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O,Dirithromycin,-,negative
112,O=C(O)c1cccnc1,Nicotinic Acid,2D6-Inhibitor,negative
113,COC1=CC(=O)C[C@@H](C)[C@]12Oc1c(Cl)c(OC)cc(OC)c1C2=O,Griseofulvin,-,negative
114,COc1cc2c3cc1Oc1cc(ccc1O)C[C@@H]1c4c(cc(OC)c(O)c4Oc4ccc(cc4)C[C@@H]3N(C)CC2)CC[N+]1(C)C,Tubocurarine,Methyltransferase-Inhibitor,negative
115,Nc1c2c(nc3ccccc13)CCCC2,Tacrine,GST-Substrate,negative
116,CCOC(C)(C)C,ethyl_tert_butyl_ether,2E1-Substrate,negative
117,CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21,Diazepam,CP2CI-Substrate,negative
118,O=C(O)C1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O.[K+].[K+].[OH-],Dipotassium clorazepate,-,negative
119,CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,Candesartan,-,negative
120,Cn1nnc2c(C(N)=O)ncn2c1=O,Temozolomide,Methyltransferase-Inhibitor,negative
121,COc1ccc2[nH]c([S@@](=O)Cc3ncc(C)c(OC)c3C)nc2c1,omeprazole_S,2C19-Substrate,negative
122,OC[C@H]1O[C@@H](n2cnc3c(O)ncnc32)[C@H](O)[C@@H]1O,Inosine,Solute_carrier_family_28_member_3-Inhibitor,negative
123,CNC(=O)c1cccc(NCC(=O)NCCc2ccc(OC)c(OC)c2)c1,Ecabapide,-,negative
124,ClC1=C(Cl)C2(Cl)C3C4CC(C5OC45)C3C1(Cl)C2(Cl)Cl,Dieldrin,-,negative
125,CC/C=C\Cn1c(=O)c2c(ncn2C)n(C)c1=O,theobromine_deriv_11,3A4-Substrate,negative
126,OCCN1CCN(CCCN2c3ccccc3C=Cc3ccccc32)CC1,Opipramol,2D6-Substrate,negative
127,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21,Chlorpromazine,2E1-Inhibitor,positive
128,CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCc1ccc(C=NNO)cc1)C1CCCCC1,Ximelagatran,2C9-Substrate,negative
129,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2,Risperidone,P450_HFLA-Substrate,negative
130,CCCCC/C=C/C/C=C/CCCCCCCC(=O)O,linoleic_acid,2E1-Substrate,negative
131,Cc1ccc(O)cc1,p_cresol,2E1-Substrate,negative
132,C=CCCCCn1c(=O)c2c(ncn2C)n(C)c1=O,theobromine_deriv_10,3A4-Substrate,negative
133,O=C1NC(c2ccccc2)(c2ccccc2)C(=O)N1COP(=O)(O)O,Fosphenytoin,-,negative
134,CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1,Chlorpropamide,2C19-Substrate,negative
135,CC(=O)N=c1sc(S(N)(=O)=O)nn1C,Methazolamide,2E1-Inhibitor,positive
136,C=C1C(=CC=C2CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)C)C[C@H](O)C[C@H]1O,Alfacalcidol,Sterol_26_hydroxylase_Sterol_27_hydroxylase_Vitamin_D3_25_hydroxylase_5_beta_cholestane_3_alpha_7_alpha12_alpha_triol_27_hydroxylase-Substrate,negative
137,O=C1C=C2CN(C(C(=O)C3CC3)c3ccccc3F)CCC2S1,R_95913,2D6-Substrate,negative
138,C[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1,Ergometrine,-,negative
139,Oc1nc2cc(Cl)ccc2o1,Chlorzoxazone,2E1-Inhibitor,positive
140,COc1ccc(-c2nc3ccc(C4=NNC(=O)CC4C)cc3[nH]2)cc1,Pimobendan,-,negative
141,Cc1ccc(O)c([C@@H](CCN(C(C)C)C(C)C)c2ccccc2)c1,Tolterodine,2D6-Substrate,negative
142,NC1=NC[C@@H]2c3ccccc3Cc3ccccc3N12,Epinastine,2D6-Inhibitor,negative
143,CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13,Nicergoline,2D6-Substrate,negative
144,CCn1nnc(C2=CCCN(C)C2)n1,LU_2509,2D6-Substrate,negative
145,COc1ccnc(CS(=O)c2nc3cc(OC(F)F)ccc3[nH]2)c1OC,Pantoprazole,SUL-Substrate,negative
146,COc1ccc(C(=O)[C@@H](C)N2CCCC2)cc1,MOPPP_R,2D6-Substrate,negative
147,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C=O)C(C)(C)CCC1,9_cis_retinal,2C19-Substrate,negative
148,Cc1c(N(C)CS(=O)(=O)[O-])c(=O)n(-c2ccccc2)n1C,Metamizole Sodium,GST-Inducer,negative
149,CC[C@H](C(N)=O)N1CCCC1=O,Levetiracetam,GST-Inducer,negative
150,CNn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C)CC3)cc21,Amifloxacin,-,negative
151,Nc1nc2[nH]cnc2c(=S)[nH]1,Tioguanine,Solute_carrier_family_28_member_3-Substrate,negative
152,NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl,Furosemide,2E1-Substrate,negative
153,C[C@@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@H]2O,Estradiol,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
154,CNCCN1C(=O)[C@H](OC(C)=O)[C@H](c2ccc(OC)cc2)Sc2ccccc21,N_desmethyl_diltiazem,3A4-Substrate,negative
155,O=C1OC2(c3ccc(OCc4ccccc4)cc3Oc3cc(OCc4ccccc4)ccc32)c2ccccc21,dibenzyl_fluorescein,2D6-Substrate,negative
156,COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC,Trimethoprim,Multidrug_and_toxin_extrusion_protein_1-Inhibitor,negative
157,O=NN(CCCl)C(=O)NC1CCCCC1,Lomustine,2D6-Substrate,negative
158,N#N,Nitrogen,Solute_carrier_family_15_member_1-Substrate,negative
159,Cl,Hydrochloric Acid,2D6-Inhibitor,negative
160,CCCCc1ncc(C=C(Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1,Eprosartan,-,negative
161,CC1(C)[C@H]2CC[C@]1(C)C(=O)C2,Camphora,GST-Inducer,negative
162,COc1c(C)c2c(c(O)c1CC=C(C)CCC(=O)O)C(=O)OC2,Mycophenolic Acid,Solute_carrier_family_22_member_6-Substrate,negative
163,COc1cc(N)c(Cl)cc1C(=O)N[C@@H]1CCN(CCCOc2ccc(F)cc2)C[C@@H]1OC,cisapride,2C8-Substrate,negative
164,Cc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3,dimemorfan,2D6-Substrate,negative
165,CC[N+](C)(CC)CCc1c(C(F)(F)F)c2ccc(OC)cc2oc1=O,MeAMFC,2D6-Substrate,negative
166,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H]([N+]3(C)CCCCC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CCCCC1,Vecuronium,Methyltransferase-Inhibitor,negative
167,CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)OCOC(=O)OC(C)C,Tenofovir Disoproxil,2E1-Inhibitor,positive
168,CCOC(=O)c1cncn1[C@@H](C)c1ccccc1,Etomidate,19A-Inhibitor,negative
169,COc1ccc(OC)c([C@@H](O)[C@@H](C)N)c1,Methoxamine,Solute_carrier_family_12_member_2-Inducer,negative
170,CC(C)NNC(=O)c1ccncc1,Iproniazide,N_acetyltransferase-Inhibitor,negative
171,COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](c6cccs6)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,Teniposide,-,negative
172,Cn1cnc2c1c(=O)[nH]c(=O)n2C,Theobromine,2E1-Substrate,negative
173,CC(c1cc2ccccc2s1)N(O)C(N)=O,Zileuton,-,negative
174,CCCCNc1cc(C(=O)O)cc(S(N)(=O)=O)c1Oc1ccccc1,Bumetanide,Solute_carrier_family_12_member_2-Inhibitor,negative
175,Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc32)cc1,Tecastemizole,-,negative
176,NCCCC(=O)O,Aminobutyric Acid,2D6-Substrate,negative
177,COc1ccc(C(c2ccc(O)c(O)c2)C(Cl)(Cl)Cl)cc1,catechol_methoxychlor,2D6-Substrate,negative
178,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=O)C(C)(C)CCC1,all_trans_retinal,2D6-Substrate,negative
179,C[C@H](COc1ccccc1)N(CCCl)Cc1ccccc1,Phenoxybenzamine,3A4-Substrate,negative
180,O=C(O)CCC/C=C\C[C@@H]1[C@@H](NS(=O)(=O)c2ccccc2)C2CC[C@@H]1C2,S_145,2C9-Substrate,negative
181,N[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(Cl)CS[C@H]12)c1ccccc1,Cefaclor,Solute_carrier_family_22_member_6-Inhibitor,negative
182,C1CNCCN1,Piperazine,2D6-Substrate,negative
183,COc1cc2c(cc1OC)C(=O)[C@H](CC1CCN(Cc3ccccc3)CC1)C2,Donepezil,2D6-Substrate,negative
184,CCCCCC,hexane,2E1-Substrate,negative
185,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C,Danazol,19A-Inhibitor,negative
186,CCN(CC)CCCN(c1ccccc1)C1Cc2ccccc2C1,Aprindine,2D6-Substrate,negative
187,N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,Letrozole,19A-Inhibitor,negative
188,CC=O,acetaldehyde,2E1-Substrate,negative
189,CC(NCC(O)COc1cccc2ccccc12)C(F)F,difluoro_propranolol,2D6-Substrate,negative
190,CC[C@@]1(c2ccc(N)cc2)CCC(=O)NC1=O,Aminogluthetimide,Steroid_17_alpha_monooxygenase_Steroid_17_alpha_hydroxylase1720_lyase-Inhibitor,negative
191,COc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314,Dihydrocodeine,2D6-Substrate,negative
192,C[C@](O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,Bicalutamide,2D6-Inhibitor,negative
193,C[C@H](CN(C)C)CN1c2ccccc2CCc2ccccc21,Trimipramine,2D6-Substrate,negative
194,COc1ccc(-c2oc3cc(O)cc(O)c3c(=O)c2O)cc1O,tamarixetin,2C9-Substrate,negative
195,CC(=O)C1CCC2C3CC=C4CC(O)CCC4(C)C3CCC12C,Pregnenolone,2D6-Substrate,negative
196,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1,9_cis_retinoic_acid,2C9-Substrate,negative
197,CN(C/C=C/C#CC(C)(C)C)Cc1cccc2ccccc12,terbinafine,2C19-Substrate,negative
198,CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21,Clomipramine,GST-Inhibitor,negative
199,Nc1nc(C(=CCC(=O)O)C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=CCS[C@@H]23)cs1,Ceftibuten,Solute_carrier_family_15_member_1-Substrate,negative
200,COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(=O)O)cc1,TR_14035,2C9-Substrate,negative
201,CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1,Tazarotene,2C8-Substrate,negative
202,Cc1nc(C)c2c(n1)N(Cc1ccc(-c3ccccc3-c3nnn[nH]3)cc1)C(=O)CC2,Tasosartan,-,negative
203,CCC[C@H](N[C@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@@H]21)C(=O)OCC,Perindopril,GST-Inhibitor,negative
204,COC(=O)C1=C(C)NC(C)=C(C(=O)OCC=Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1,Pranidipine,-,negative
205,COc1ccc2c3c1O[C@H]1C(OC(C)=O)=CC[C@@H]4[C@@H](C2)N(C)CC[C@@]341,Thebacon,2D6-Substrate,negative
206,CCCCN(C)N=O,NN_methyl_butyl_nitrosoamine,2E1-Substrate,negative
207,CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,Timolol,2D6-Substrate,negative
208,CN1C2CCC1CC(OC(c1ccccc1)c1ccccc1)C2,Benzatropine,2D6-Substrate,negative
209,C[C@]12CC[C@@H]3c4ccc(O)cc4C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@H]3[C@@H]1CC[C@@H]2O,Fulvestrant,3A4-Substrate,negative
210,CCCC(=O)O[C@H]1[C@H](C)O[C@@H](O[C@@H]2[C@@H](C)O[C@@H](O[C@@H]3[C@@H](OC)[C@H](O)CC(=O)O[C@H](C)CC=CC=C[C@H](O)[C@H](C)C[C@@H]3CC=O)[C@H](O)[C@H]2N(C)C)C[C@@]1(C)OC(=O)CC,Rokitamycin,-,negative
211,CC(NCC(O)COc1cccc2ccccc12)C(F)(F)F,trifluoro_propranolol,2D6-Substrate,negative
212,CN1CCCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,Homochlorcyclizine,-,negative
213,CC(C)COC[C@H](CN(Cc1ccccc1)c1ccccc1)N1CCCC1,Bepridil,2D6-Substrate,negative
214,C=C1CC[C@H](O)CC1=CC=C1CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)C=C[C@H](C)C(C)C,Ergocalciferol,Arachidonic_acid_epoxygenase-Substrate,negative
215,Cc1c2ccccc2nc2c1ccc1ccccc12,7_methyl_benzacridine,1A2-Substrate,negative
216,CNC(=O)Oc1cc(C)c(SC)c(C)c1,Methiocarb,2D6-Substrate,negative
217,C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)/C=C/[C@H](C)C(C)C)C[C@@H](O)C[C@@H]1O,1_alpha_hydroxy_vitamin_D2,3A4-Substrate,negative
218,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,Metandienone,3A4-Substrate,negative
219,CN(C)C(=O)Oc1ccc[n+](C)c1,Pyridostigmine,3A4-Inducer,negative
220,CCN(CC)CCOCCOC(=O)C1(c2ccccc2)CCCC1,Pentoxyverine,2D6-Substrate,negative
221,CCC(=O)O[C@@H]1CC(=O)O[C@H](C)C/C=C/C=C/[C@H](OC(C)=O)[C@H](C)C[C@H](CC=O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@H]1OC,miocamycin_Mb2,3A4-Substrate,negative
222,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,Nilotinib,UGT-Inhibitor,negative
223,O=C(O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl,Tienilic Acid,GST-Inhibitor,negative
224,O=C(N[C@H](CO)[C@H](O)c1ccc([N+](=O)[O-])cc1)C(Cl)Cl,Chloramphenicol,-,negative
225,CCOC(=O)C=C(C)C=CC=C(C)C=Cc1c(C)cc(OC)c(C)c1C,Etretinate,19A-Inhibitor,negative
226,CC1O[C@@]2(CS1)CN1CCC2CC1,Cevimeline,2D6-Substrate,negative
227,Cc1cc(CCCOc2c(C)cc(-c3noc(C(F)(F)F)n3)cc2C)on1,Pleconaril,P450_HFLA-Inducer,negative
228,Cc1nnc2n1-c1sc(Br)cc1C(c1ccccc1Cl)=NC2,Brotizolam,-,negative
